4.Atypical extraventricular neurocytoma: report of a case.
Yan LI ; Jing FU ; Yanke GUO ; Zhichao WANG
Chinese Journal of Pathology 2014;43(11):774-775
5.Plasmacytoid-like oncocytic carcinoid of lung: report of a case.
Yongliang TENG ; Yabin ZOU ; Xu YAN ; Dianbo CAO ; Liang GUO
Chinese Journal of Pathology 2015;44(5):344-345
6.Primary intracranial mxyoid liposarcoma: report of a case.
Liang GUO ; Dian-bo CAO ; Xu YAN ; Ya-bin ZOU ; Hong-xi MA
Chinese Journal of Pathology 2013;42(12):843-844
7.Application of negative pressure attraction method of brushing and washing in oral care of patients with orotracheal intubation
E FENG ; Yan-Ling YIN ; Xin-Rong GUO ; Hui-Ling ZHENG
Chinese Journal of Modern Nursing 2012;18(11):1280-1282
Objective To explore the effect of negative pressure attraction method of brushing and washing apply in oral care of patients with orotracheal intubation.Methods Totals of 82 oral intubation patients in ICU were randomly selected and divided into experience group ( n =42 ) and control group ( n =40 ).The traditional method of oral care was used in control group,while the negative pressure attraction method of brushing and washing was used in experience group,then,the incidence of oral infections,ventilator-associated pneumonia( VAP),dental plaque and oral mucosal injury were observed in two groups.Results The incidence of oral infections,ventilator-associated pneumonia(VAP),dental plaque in experience group respectively were 7.14%,2.38%,4.76%,and that in control group were 22.50%,15.00%,32.50%,the differences were statistically significant ( x2 =3.88,4.18,10.55,respectively; P < 0.05 ),while there was no significant difference in the incidence of oral mucosal injury between two groups ( P > 0.05 ).Conclusions The negative pressure attraction method of brushing and washing can effectively keep the oral clean of patients with orotracheal intubation,reduce the incidence of oral infections and ventilator-associated pneumonia and dental plaque,when compared with the traditional method of oral care.
8.Construction and identification of the two lentiviral eukaryotic expression vectors of pEGFP-N1-HIF-lα and pEGFP-N1-muHIF-1α
Shu-Hong WANG ; Xiong ZHANG ; Jin-E ZHANG ; Hua-Yan GUO ; Na GUO ; Yuan-Liang HUANG
Chinese Journal of Stomatology 2012;47(z1):244-247
Objective To construct two lentiviral eukaryotic expression vectors of pEGFP-N1-HIF-1α and pEGFP-N1-muHIF-1α and identificate the gene sequences.Methods Primers were designed according to wild-type human HIF-1 α gene sequence information and determined restriction sites of human HIF-1α point mutant sequence,taking human HIF-1α and constructed HIF-1α gene mutant clone as a template for polymerase chain reaction(PCR) amplification.Then,the target gene PCR product and purpose vector were digested.Adapter-ligated fragments of the target fragment with purpose vector were transformed into DH-5α competent cells using the recombinant PCR methods.Finally,the positive clones were selected and sequenced to verify whether the sequence of insert fragments in recombinant clones was consistent with oligo sequences designed or not.Results Through recombinant clone colony PCR,enzyme digestion of the recombinant clones and plasmid cloning and sequencing,the fragment sequences inserted in recombinant clones were consistent with the designed oligo sequences.Conclusions The two lentiviral eukaryotic expression vectors of pEGFP-N1-HIF-1α and pEGFP-NI-muHIF-1α were successfully constructed and applicable for follow-up experiments on transfection of bone marrow mesenchymal stem cells.
9.Nemaline myopathy: report of a case.
Hong-ran WU ; Xing LIU ; Li-yan SUN ; Yi BU ; Yan-su GUO ; Dong-xia WU ; Xue-qin SONG
Chinese Journal of Pathology 2013;42(6):407-408
10.Supra-molecular assembly and magnetic targeted slow-release effect of "dextran-magnetic layered double hydroxide-fluorouracil" drug delivery system.
Guo-jing GOU ; Yan-hong LIU ; Yue SUN ; Je HUANG ; Bing XUE ; Li-e DONG
Acta Pharmaceutica Sinica 2011;46(11):1390-1398
The drug-loading system of DMF (dextran - magnetic layered double hydroxide - fluorouracil) was synthesized by "co-precipitation intercalated assembly - dextran composite in situ - solvent conversion" technology. The crystal-phase characteristic and slow-release performance of DMF were investigated through X-ray diffraction (XRD), infrared spectrum (IR), transmission electron microscopy (TEM), thermogravimetry (TG) and in vitro release experiment. The targeted transshipment and slow-release effect of DMF system were evaluated by in vivo animal experiment. It was showed that the XRD of DMF matched with R-sixtetragonum type layered double hydroxide and Fd-3m cubic type ferrite. IR test demonstrated that the DMF system was a supra-molecular complex consisted of Dextran (DET), magnetic layered double hydroxide (MLDH) and fluorouracil (FU) components. The two-level supra-molecular MLDH-FU presented six-edge lozenge TEM morphology, with layered characteristics. DET on the surface of DMF was capable of protecting the layered structure of MLDH-FU, improving particle dispersion properties, and strengthening the slow-release performance of the drug delivery system. The drug release model of DMF at pH 7.35 of PBS in vitro fit to the zero-order kinetics equation C = 1.1716 x 10(-5) + 4.4626 x 10(-7) t. The drug delivery system DMF could transport drugs principally to in vivo target organs with a local effect, targeted specificity, and excellent circulation transshipment performance. The pharmacokinetic process of DMF presented multi-peak phenomenon with peak attenuation and cyclic growth. The peaks appeared at 0.25, 1, 3, 5 and 9 d separately after dosing intervention. The first peak process of DMF accorded with a pharmacokinetic equation of C(FU) = 14.34 e(-0.530t) + 36.04 e(-0.321t) + 24.18 e(-0.96t), and presented the characteristic of slow absorption and fast elimination. As for subsequent peak processes, half-life increased, bioavailability increased, and plasma clearance decreased. The highest peak value of DMF was 1/37 of original value of FU, and the relative bioavailability was 419% to original FU.
Animals
;
Biological Availability
;
Delayed-Action Preparations
;
Dextrans
;
chemistry
;
Drug Carriers
;
Female
;
Fluorouracil
;
administration & dosage
;
chemistry
;
pharmacokinetics
;
Half-Life
;
Hydroxides
;
chemistry
;
Magnetics
;
Male
;
Microscopy, Electron, Transmission
;
Rats
;
Rats, Sprague-Dawley
;
Spectrophotometry, Infrared
;
Thermogravimetry
;
X-Ray Diffraction